Tyrosine kinase inhibitors (TKIs) have improved outcome for many tumors. Although better
tolerated than cytotoxic chemotherapy, they may cause several adverse events (AEs) and
various endocrine-related toxicities have been reported under TKI treatment. The toxicity
profile varies between the different TKI compounds. This review focuses on the main
endocrinopathies caused by TKIs. Thyroid dysfunction, and in particular hypothyroidism, is
the most frequent and best described. Several potential mechanisms have been …